Trial Profile

A Phase I/II clinical trial evaluating DCVax-Direct, autologous activated dendritic cells for intratumoral injection, in patients with solid tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 11 Jun 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dendritic cell vaccine-Northwest Biotherapeutics (Primary)
Indications Colorectal cancer; Liver cancer; Malignant melanoma; Pancreatic cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Northwest Biotherapeutics

04 Jun 2019 According to a Northwest Biotherapeutics media release, follow-up data from the trial was presented in the Industry Expert Theater presentation at the 55th annual ASCO Conference 2019.
17 Jul 2018 Results (n=39) from part 1 of this trial published in the Clinical Cancer Research
29 May 2018 According to a Northwest Biotherapeutics media release, company has completed the 40-patient Phase I portion of the trial, and is preparing for the Phase II portion.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com